Clinical trials: Exudative Macular Degeneration
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
The study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab…
- Conditions
- Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
- Trial name
- NORSE SEVEN (NCT05112861)
- Testing
- bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Outlook Therapeutics, Inc.
Exudative Macular Degeneration
Pilot Study of X-82 in Patients With Wet AMD
The objective of this study is to evaluate the safety and preliminary biologic activity/efficacy of X-82 in patients with wet Age-related Macular Degeneration (AMD).
- Trial name
- NCT01674569
- Testing
- X-82 oral, ranibizumab (Lucentis)
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tyrogenex
Age Related Macular Degeneration
Visual Function Tests in Age-related Macular Degeneration
The goal of this study is to assess a battery of visual function tests in subjects with non-exudative age-related macular degeneration
- Trial name
- NCT03275753
- Testing
- Visual Function Tests
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Pigment Epithelial Detachment
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary…
- Trial name
- PED (NCT01334255)
- Testing
- iSONEP (sonepcizumab/LT1009)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Lpath, Inc.
Age-related Macular Degeneration
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness among adults in North America. The current standard of care for patients with exudative ("wet") AMD is anti-vascular endothelial growth factor (anti-VEGF)…
- Trial name
- NCT03869684
- Testing
- MT-0814
- Where
- 13 sites in United States
- Volunteers
- 13 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
ADVM-022 Intravitreal Gene Therapy for Wet AMD
ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product developed for the treatment of neovascular (wet) age-related macular degeneration (wet AMD).
- Trial name
- OPTIC (NCT03748784)
- Testing
- ADVM-022
- Where
- 11 sites in United States
- Volunteers
- 30 people
- Sponsor
- Adverum Biotechnologies, Inc.
Wet Macular Degeneration
To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
To describe the use of intravitreal aflibercept in routine clinical practice and to describe follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical practice in Canada for a study population of…
- Trial name
- PEGASUS (NCT02540369)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 2,150 people
- Sponsor
- Bayer
Non-exudative (Dry) Age-related Macular Degeneration (AMD)
HELP Therapy for Dry AMD
This is an open-label, single center clinical investigation to evaluate the efficacy and safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a treatment for non-exudative (dry) Age-related…
- Trial name
- HELPuc (NCT01840683)
- Testing
- H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- B.Braun Avitum AG
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT03834753
- Testing
- bevacizumab, ranibizumab
- Where
- 50 sites in United States
- Volunteers
- 228 people
- Sponsor
- Outlook Therapeutics, Inc.
Macular Degeneration, Maculopathy, Age-Related
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
- Trial name
- NCT00058994
- Testing
- anecortave acetate
- Where
- United States
- Sponsor
- Alcon Research
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
- Trial name
- NCT04645212
- Testing
- ADVM-022
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Adverum Biotechnologies, Inc.
Age-Related Macular Degeneration, Wet Macular Degeneration
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
The purpose of this study is to confirm the clinical and economic benefits of IRay treatment with respect to the number of anti-VEGF injections and frequency of visits during the first year after treatment for patients with wet…
- Conditions
- Age-Related Macular Degeneration, Wet Macular Degeneration, Macular Degeneration, Eye Diseases
- Trial name
- ENDEAVOUR (NCT01521065)
- Testing
- IRay
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Oraya Therapeutics, Inc.
Neovascular Age-related Macular Degeneration
Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD
Double-masked, uncontrolled, multi-center, study in which participants will be randomized to one of 3 doses of topical ocular PAN 90806 administered once daily for 12 weeks.
- Trial name
- NCT03479372
- Testing
- PAN-90806 Ophthalmic Suspension
- Where
- 18 sites in United States, Czechia and 3 more
- Volunteers
- 51 people
- Sponsor
- PanOptica, Inc.
Neovascular (Wet) Age-Related Macular Degeneration
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.
- Trial name
- NCT05197270
- Testing
- 4D-150 IVT, Aflibercept IVT
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 215 people
- Sponsor
- 4D Molecular Therapeutics
Wet Macular Degeneration
A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration
The present trial will use an open label design to investigate the effect of BI 144807 on central 1-mm retinal thickness and presence of neovascular leakage in newly diagnosed wAMD patients.
- Trial name
- NCT02121522
- Testing
- BI 144807
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Macular Degeneration
A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration
The general objective of this study is to evaluate the safety and efficacy of ophthalmic intravitreal injections of ALG-1001 in human subjects with wet age-related macular degeneration (Wet AMD).
- Trial name
- NCT01749891
- Testing
- ALG 1001
- Where
- Mexico
- Volunteers
- 25 people
- Sponsor
- Allegro Ophthalmics, LLC
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT03844074
- Testing
- bevacizumab, ranibizumab
- Where
- 9 sites in Australia
- Volunteers
- 61 people
- Sponsor
- Outlook Therapeutics, Inc.
Exudative Age-Related Macular Degeneration
ESBA1008 Microvolume Study
The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration (AMD).
- Trial name
- NCT01849692
- Testing
- ESBA1008 solution, Ranibizumab
- Volunteers
- 107 people
- Sponsor
- Alcon Research